EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M Younossi, Markos Kalligeros, Linda Henry

Clinical and Molecular Hepatology · 28.02.2025 · 31 (Suppl) · S32-S50

DOI: 10.3350/cmh.2024.0431 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2025. Verfasst von Zobair M Younossi und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH Council, Washington DC, USA. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 1065-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Intercept, Cymabay, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD). Currently, 38% of all adults and 7–14% of children and adolescents have MASLD. By 2040, the MASLD prevalence rate for adults is projected to increase to more than 55%. Although MASLD does not always develop into progressive liver disease, it has become the top indication for liver transplant in the United States for women and those with hepatocellular carcinoma (HCC). Nonetheless, the most common cause of mortality among patients with MASLD remains cardiovascular disease. In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers. Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden. Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients. Although several obesity and T2D drugs are available to treat co-morbid disease, resmetirom is the only MASH-targeted medication for patients with stage 2–3 fibrosis that has approved by the Food and Drug Administration for use in the United States. This review discusses MASLD epidemiology and its related risk factors and outcomes and demonstrates that without further global initiatives, MASLD incidence could continue to increase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHumansDiabetes Mellitus, Type 2ObesityRisk FactorsLiver NeoplasmsPrevalenceCarcinoma, Hepatocellular

Stichwörter der Autor:innen

Insulin resistanceMASLDMetabolic syndromeType 2 diabetes

Autor:innen und Institutionen

  • The Global NASH Council, Washington DC, USA.
  • Beatty Liver and Obesity Program, Inova Health System, Falls Church, VA, USA.
  • Center for Outcomes Research in Liver Disease, Washington DC, USA.
  • Beth Israel Deaconess Medical Center, Harvard University, Cambridge, MA, USA.

Förderung

  • Intercept
  • Cymabay
  • Boehringer Ingelheim
  • Ipsen
  • BMS
  • GSK
  • NovoNordisk
  • Siemens

Zitieren

APA

Younossi, Z. M., Kalligeros, M., & Henry, L. (2025). Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 31(Suppl), S32-S50. https://doi.org/10.3350/cmh.2024.0431

Vancouver

Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2025;31(Suppl):S32-S50. doi:10.3350/cmh.2024.0431

BibTeX
@article{Younossi2025,
  author = {Younossi, Zobair M and Kalligeros, Markos and Henry, Linda},
  title = {Epidemiology of metabolic dysfunction-associated steatotic liver disease},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {Suppl},
  pages = {S32--S50},
  doi = {10.3350/cmh.2024.0431}
}
Kostenlos starten →